{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:01:19Z","timestamp":1789664479714,"version":"4.0.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tuberculosis preventive treatment (TPT) is essential for reducing the progression of latent tuberculosis infection (LTBI) to active disease, yet real-world implementation often faces substantial attrition. This study evaluated the acceptance, completion, and safety of the 3-month daily isoniazid plus rifampicin regimen (3HR) among close contacts in a high-burden setting in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a prospective observational cohort study among tuberculin skin test\u2013positive close contacts from January 2024 to June 2025. Participants voluntarily chose to initiate or decline 3HR. Acceptance, completion, and adverse events (AEs) were prospectively recorded. Multivariable logistic regression models were used to identify predictors of uptake and completion, and a sensitivity analysis assessed the differential impact of hepatic versus non-hepatic AEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 617 eligible contacts, 520 (84.3%) accepted TPT. Acceptance was significantly higher among school than household contacts (96.0% vs. 76.1%;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001), and school contact status was the strongest predictor of uptake (adjusted odds ratio [aOR] 14.20; 95% CI 5.48\u201336.82). Among the 520 initiators, 382 (73.5%) completed treatment. Demographic factors were not associated with completion, whereas AEs markedly reduced completion (aOR 0.25; 95% CI 0.14\u20130.44). A total of 56 participants (10.8%) experienced at least one AE; hepatic events were the most frequent (73.2%) and accounted for most discontinuations. Subjective intolerance far exceeded clinically confirmed AEs (75 vs. 20). Sensitivity analyses confirmed that both hepatic and non-hepatic AEs independently reduced completion.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world implementation evaluation, the 3HR regimen demonstrated high programmatic acceptance, particularly in school settings; however, treatment completion was constrained by both perceived and clinically verified AEs. These findings suggest that optimizing TPT delivery requires strengthened safety monitoring, structured symptom counseling, and targeted mobilization strategies to improve uptake, particularly among household contacts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1794409","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:24:23Z","timestamp":1776662663000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Acceptance, completion, and safety of the 3HR regimen for latent tuberculosis infection: a prospective cohort study in China"],"prefix":"10.3389","volume":"14","author":[{"given":"Qingfeng","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Tuberculosis, Guangxi Zhuang Autonomous Region Chest Hospital","place":["Liuzhou, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Public Health, Guangxi Zhuang Autonomous Region Chest Hospital","place":["Liuzhou, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Science and Education, Guangxi Zhuang Autonomous Region Chest Hospital","place":["Liuzhou, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhen","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Public Health, Guangxi Zhuang Autonomous Region Chest Hospital","place":["Liuzhou, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuchun","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Public Health, Guangxi Zhuang Autonomous Region Chest Hospital","place":["Liuzhou, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Tuberculosis, Guangxi Zhuang Autonomous Region Chest Hospital","place":["Liuzhou, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Tuberculosis, Guangxi Zhuang Autonomous Region Chest Hospital","place":["Liuzhou, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"ref1","volume-title":"Global Tuberculosis Report 2025","year":"2025"},{"key":"ref2","volume-title":"The End TB Strategy: Global Strategy and Targets for Tuberculosis Prevention, Care and Control after 2015","year":"2015"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1900655","DOI":"10.1183\/13993003.00655-2019","article-title":"The global prevalence of latent tuberculosis: a systematic review and meta-analysis","volume":"54","author":"Cohen","year":"2019","journal-title":"Eur Respir J"},{"key":"ref4","article-title":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management","year":"2018"},{"key":"ref5","volume-title":"WHO Consolidated Guidelines on Tuberculosis: Module 1: Prevention \u2013 Tuberculosis Preventive Treatment","year":"2024"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"6462","DOI":"10.1038\/s41598-020-63156-8","article-title":"Adherence to nine-month isoniazid for latent tuberculosis infection in healthcare workers: a prospective study in a tertiary hospital","volume":"10","author":"Chung","year":"2020","journal-title":"Sci Rep"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1097\/JCMA.0000000000000605","article-title":"Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: a systematic review and meta-analysis","volume":"84","author":"Tseng","year":"2021","journal-title":"J Chin Med Assoc"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/jac\/dky403","article-title":"Cost-effectiveness of 3\u202fmonths of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study","volume":"74","author":"Doan","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S2213-2600(23)00096-6","article-title":"Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis","volume":"11","author":"Winters","year":"2023","journal-title":"Lancet Respir Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3760\/cma.j.cn112147-20240328-00173","article-title":"Expert consensus on tuberculosis preventive treatment for individuals at high risk of developing active diseases from latent tuberculosis infection in comprehensive medical facilities","volume":"47","year":"2024","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/j.ijid.2020.02.034","article-title":"Management of latent tuberculosis infection in China: exploring solutions suitable for high-burden countries","volume":"92","author":"Cui","year":"2020","journal-title":"Int J Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.46234\/ccdcw2022.050","article-title":"Acceptability of tuberculosis preventive treatment strategies among healthcare workers using an online survey \u2013 China, 2021","volume":"4","author":"Fa","year":"2022","journal-title":"China CDC Wkly"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12879-023-08005-5","article-title":"Factors associated with refusal of preventive therapy after initial willingness to accept treatment among college students with latent tuberculosis infection in Shandong, China","volume":"23","author":"Yuan","year":"2023","journal-title":"BMC Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.46234\/ccdcw2021.009","article-title":"Guidelines for the prevention and control of tuberculosis in schools: Recommendations from China CDC","volume":"3","author":"Xia","year":"2021","journal-title":"China CDC Wkly."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S1473-3099(17)30402-4","article-title":"Incidence of active tuberculosis in individuals with latent tuberculosis infection in rural China: follow-up results of a population-based, multicentre, prospective cohort study","volume":"17","author":"Gao","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of Antituberculosis therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41592-019-0686-2","article-title":"SciPy 1.0: fundamental algorithms for scientific computing in Python","volume":"17","author":"Virtanen","year":"2020","journal-title":"Nat Methods"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41586-020-2649-2","article-title":"Array programming with NumPy","volume":"585","author":"Harris","year":"2020","journal-title":"Nature"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","article-title":"The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis","volume":"16","author":"Alsdurf","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e1003703","DOI":"10.1371\/journal.pmed.1003703","article-title":"The latent tuberculosis cascade-of-care among people living with HIV: a systematic review and meta-analysis","volume":"18","author":"Bastos","year":"2021","journal-title":"PLoS Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.21037\/jtd.2018.06.138","article-title":"Effects of preventive therapy for latent tuberculosis infection and factors associated with treatment abandonment: a cross-sectional study","volume":"10","author":"Huang","year":"2018","journal-title":"J Thorac Dis"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e0185646","DOI":"10.1371\/journal.pone.0185646","article-title":"ESMPE: a combined strategy for school tuberculosis prevention and control proposed by Dalian, China","volume":"12","author":"Wang","year":"2017","journal-title":"PLoS One"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40249-016-0102-4","article-title":"Disparity in reimbursement for tuberculosis care among different health insurance schemes: evidence from three counties in Central China","volume":"5","author":"Pan","year":"2016","journal-title":"Infect Dis Poverty"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12889-017-4089-y","article-title":"Financial barriers and coping strategies: a qualitative study of accessing multidrug-resistant tuberculosis and tuberculosis care in Yunnan, China","volume":"17","author":"Hutchison","year":"2017","journal-title":"BMC Public Health"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1265057","DOI":"10.3389\/fmed.2023.1265057","article-title":"Latent tuberculosis infection treatment completion in Biscay: differences between regimens and monitoring approaches","volume":"10","author":"Ortiz Laza","year":"2023","journal-title":"Front Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1046\/j.1365-2648.2003.02712.x","article-title":"Health belief model and reversal theory: a comparative analysis","volume":"43","author":"Finfgeld","year":"2003","journal-title":"J Adv Nurs"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1371\/journal.pmed.0040238","article-title":"Patient adherence to tuberculosis treatment: a systematic review of qualitative research","volume":"4","author":"Munro","year":"2007","journal-title":"PLoS Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1146\/annurev-pharmtox-022723-112425","article-title":"The nocebo effect","volume":"64","author":"Colloca","year":"2024","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e0155147","DOI":"10.1371\/journal.pone.0155147","article-title":"Psychological and educational intervention to improve tuberculosis treatment adherence in Ethiopia based on health belief model: a cluster randomized control trial","volume":"11","author":"Tola","year":"2016","journal-title":"PLoS One"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"CD006591","DOI":"10.1002\/14651858.CD006591.pub2","article-title":"Patient education and counselling for promoting adherence to treatment for tuberculosis","volume":"2012","author":"M\u2019imunya","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e1004091","DOI":"10.1371\/journal.pmed.1004091","article-title":"Improving cascade outcomes for active TB: a global systematic review and meta-analysis of TB interventions","volume":"20","author":"Marley","year":"2023","journal-title":"PLoS Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1800395","DOI":"10.1183\/13993003.00395-2018","article-title":"3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review","volume":"52","author":"Assefa","year":"2018","journal-title":"Eur Respir J"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"CD007545","DOI":"10.1002\/14651858.CD007545.pub2","article-title":"Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB","volume":"2013","author":"Sharma","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"ref35","first-page":"1235","article-title":"Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada","volume":"12","author":"Hirsch-Moverman","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12955-019-1228-4","article-title":"Quality of life of patients on treatment for latent tuberculosis infection: a mixed-method study in Stockholm, Sweden","volume":"17","author":"Shedrawy","year":"2019","journal-title":"Health Qual Life Outcomes"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e0003306","DOI":"10.1371\/journal.pgph.0003306","article-title":"Optimizing the cascade of prevention to protect people from tuberculosis: a potential game changer for reducing global tuberculosis incidence","volume":"4","author":"Matteelli","year":"2024","journal-title":"PLoS Glob Public Health"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1186\/s12879-025-11503-3","article-title":"The impact of digital adherence technologies on treatment outcomes, adherence, and patient-reported outcomes in tuberculosis: a systematic review and meta-analysis","volume":"25","author":"Mohamed","year":"2025","journal-title":"BMC Infect Dis"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.3389\/fphar.2019.01667","article-title":"Molecular biomarkers in drug-induced liver injury: challenges and future perspectives","volume":"10","author":"Fu","year":"2019","journal-title":"Front Pharmacol"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1794409\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:24:25Z","timestamp":1776662665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1794409\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":39,"alternative-id":["10.3389\/fpubh.2026.1794409"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1794409","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"article-number":"1794409"}}